Background. The most serious criticisms leveled at bacteriophage therapy are as follows: phages induce neutralizing antibodies, phages are active only when administered shortly after bacterial infection, and phage-resistant bacteria emerge rapidly in the course of therapy.
Methods. Phages lytic for several Salmonella enterica serovars were isolated by means of standard protocols from feces of patients with gastroenteritis. Growth of S. enterica serovar Paratyphi B (Salp572 f1S ) in the presence of phage f1 (selected from among 8 phages for its larger host range) provided a phage f1-resistant bacterial strain (Salp572 ). The properties of the Salp572 f1S and Salp572 f1R strains and of phage f1 were studied in a mouse model of experimental infection.
Results. Phages induced nonneutralizing antibodies and were active 2 weeks after experimental infection of mice; phage-resistant bacteria were avirulent and short lived in vivo. More importantly, phage-resistant bacteria were excellent vaccines, protecting against lethal doses of heterologous S. enterica serovars.
Conclusions. Phage therapy effectiveness has not yet been properly assessed.
Salmonella enterica lives in the gastrointestinal (GI) tracts of mammals, birds, and reptiles and can survive for a long time in water or soil or within foods. Most human cases of salmonellosis are caused by ingestion of food (primarily animal food but also fruits and vegetables) contaminated with animal feces. Clinical manifestations of human salmonellosis range from subclinical gastroenteritis to severe bacteremia, meningitis, and other forms of extraintestinal infections [1] . The more than 2,300 known serovars of S. enterica [2] in fact display great differences in virulence [3] . Because of the widespread presence of antibiotic resistance among S. enterica isolates [1] , fluoroquinolone and third-generation cephalosporins are the only antibiotics available for the treatment of clinically severe forms of S. enterica infection [1] , hence the great need for antimicrobial alternatives to antibiotics. This study explores the potential of bacteriophage therapy against S. enterica serovars. Originally, the phage specificity for a single bacterial species or serovar [4] was exploited for classifying S. enterica bacteria [5] . More recently, phages have been used for the control of S. enterica contamination in poultry [6] [7] [8] , sprout seeds [9] , and fresh-cut fruit [10] . In 2008, the US Food Safety and Inspection Service approved a Salmonella-specific phage preparation to reduce the contamination level of live poultry before processing [11] .
Production of neutralizing antibodies [12, 13] , rapid emergence of phage-resistant bacterial strains [12] [13] [14] [15] , and efficacy of phages only when administered shortly after bacterial infection [16] are the most frequent criticisms of the clinical use of phages. This study describes a phage lytic to S. enterica Paratyphi B that is without the above limitations. This study also describes a phageresistant strain of S. enterica that confers cross-protection against lethal doses of heterologous serovars.
METHODS

Bacteria.
The study included 18 S. enterica fecal isolates derived from patients with gastroenteritis. Isolates [CFUs] ). Adsorption rate, latent period, and phage burst tests were performed as described elsewhere [19] . Phage purification was performed as described elsewhere [20] .
Mice. Experiments were performed on female BALB/c mice. Phages (10 7 plaque-forming units [PFUs] in 100 mL of saline) were inoculated intravenously. The main target organs of the S. enterica isolates used in this study (liver and GI tract) were dissected and weighed. One gram of each sample was homogenized in 1 mL of saline and serially diluted in saline. CFUs were evaluated by plating each dilution on a lawn of S. enterica.
S. enterica transformation. The green fluorescent protein (GFP) gene was cloned into the HindIII-PstI sites of the pUC19 plasmid and then introduced into the Salp572 f1S strain by electroporation as described elsewhere [21] . In vivo experiments demonstrated that transformation did not statistically significantly influence the virulence of the Salp572 f1S strain.
Phage-neutralization test. Phage f1 (10 5 PFUs suspended in 100 mL of saline) was incubated with rat anti-f1 antiserum (diluted 10 Ϫ2 and in saline) for 3 h at room temper-
Ϫ2
5 ϫ 10 ature. Bacteria (10 5 CFUs in 1 mL of LB broth) were added to the antibody-coated phage particles, and the mixture was incubated for 3 h at 37ЊC. CFUs and PFUs were then counted.
Real-time reverse-transcription PCR (RT-PCR).
Reactions were performed in 20 mL of reaction mixture in triplicate with the following thermal profile: 95ЊC for 10 min and 45 cycles of 15 s at 95ЊC and 45 s at 60ЊC; 1 min at 60ЊC; and 15 s at 95ЊC plus 0.3ЊC at each step of the melting curve. The relative quantification of gene expression was calculated using the relative standard method, with the glyceraldehyde-3-phosphate dehydrogenase gene (gapA for virulence genes and gapdh for cytokine genes) used as an endogenous control. The sequences of PCR primers used (0.2 mmol/L each) are reported in Table 1.
Other methods. Restriction endonucleases analysis-pulsedfield gel electrophoresis of wild and mutant Salmonella strains was performed as described elsewhere [22, 23] . Bacteria were prepared for electron microscopy examination as described elsewhere [24] . Mice infected with GFP-labeled bacteria were analyzed using the Leica Macrofluo instrument (Wetzlar) equipped with the Leica application suite software (version 3.1.0). The O-antigen was detected by the slide agglutination test (using antiserum from Staten Serum Institut [Copenhagen, Denmark]). Survival rates of mice were analyzed using the Fisher exact test. Bacterial counts and cytokines levels were analyzed using the Student t test.
RESULTS
Phage isolation and in vitro characterization. Two samples of feces were diluted with sterile phosphate-buffered saline and filtered through a 0.22-mm filter. Serial dilutions of the filtrates were then tested for the presence of phages on LB agar plates against a panel of 18 S. enterica isolates. Of the 8 phages isolated, Figure 1 . Characteristics of bacteriophage f1 and of the phage f1-susceptible Salp572 f1S and phage f1-resistant Salp f1R bacterial strains. A, Lytic activity of the 8 phages isolated in the course of the study. The experiments described in the study were performed with the use of phage f1. "Control" refers to the bacterial strain Salp572 f1S grown in the absence of phage f1. B, Genome size of phage f1. Pulsed-field gel electrophoresis (PFGE) was run at 10؇C with a pulse ramping between 1 and 10 s for 16 h using Lambda DNA (Promega) as a marker. C, Anti-inflammatory activity of phage f1. Twenty-four hours after treatment with phage f1, Salp572 f1S -infected mice displayed statistically significantly reduced levels of proinflammatory cytokines, compared with mice infected with Salp572 f1S but not treated with phage f1. D, PFGE profiles of the Salp572 f1S (left) and Salp572 f1R (right) strains. The identical PFGE patterns reflect the common origin of the 2 strains. Restriction fragments were resolved in a single run at a constant voltage of 6 V cm 2 and an orientation angle of 120؇ between electric fields for 20 h with a pulse ramping between 1 and 15 s. IFNg, interferon g; OD 600 nm , optical density at 600 nm; TNF-a, tumor necrosis factor a. f1 was chosen for further studies in view of its higher in vitro lytic activity ( Figure 1A ) and larger host range (Table 2) . Phage f1 was further characterized with regard to the adsorption rate ( mL/min), latent period (30 min), burst size (10 2 8 1.6 ϫ 10 PFUs), and genome size ( Figure 1B ). Incubation of f1 with an excess of mouse anti-f1 antibodies did not interfere with phage's capacity to lyse susceptible bacteria. This result demonstrates that the antibodies elicited by f1 are nonneutralizing.
Phage f1 activity in vivo. Two groups of mice (10 mice per group) were injected intravenously with a lethal dose (10 7 CFUs per mouse) of a phage f1-susceptible isolate of S. enterica serovar Paratyphi B (for brevity referred to as Salp572 f1S ). One group of infected mice was used as the untreated control, whereas the second group was injected intravenously with phage f1 (10 7 PFUs per mouse) immediately after infection. The animals of the control group all died within 48 h after infection. The mice treated with the phage all survived. Cumulative results from 3 independent experiments showed that although 100% (30 of 30) of the mice of the control group died, none (0 of 30) of the phage-treated mice died. The clinical advantage of phage therapy was also evident on quantifying the bacterial load in the blood and in the 2 organs most heavily infected with Salp572 f1S (liver and GI tract). Control mice displayed a high bacterial load (mean bacterial load ‫ע‬ standard deviation [SD] , CFU/mL in the blood and 6 6 4 ϫ 10 ‫ע‬ 0.20 ϫ 10 CFU/g in the GI tract), whereas no bacteria 6 6 6 ϫ 10 ‫ע‬ 0.3 ϫ 10 Table 2 .
Properties of the 8 Isolated Bacteriophages
Bacteriophage Salmonella enterica serovar f1 f2 f3 f4 f5 f6 f7 f8
Paratyphi B, 001 were isolated from the blood, GI tracts, or livers of phagetreated mice. In addition, phage f1 statistically significantly reduced inflammation in Salmonella-infected mice ( Figure 1C) .
Efficacy of phage f1 delayed treatment. The above experiment demonstrated that f1 is active in vivo, at least when administered immediately after infection. Because bacterial infections are typically caused by a small initial inoculum, to be clinically useful, phage therapy must also be effective when started weeks after infection. To see whether f1 displayed this potential, mice were infected with a sublethal dose of Salp572 f1S (10 5 CFUs per mouse) and treated with phage f1 (10 7 PFUs per mouse) 2 weeks later. In this experiment, the parameter to measure the efficacy of the therapy was the ability of phage f1 to sterilize the animals (rather than the ability to rescue the animals from a lethal bacterial dose, as in the above-described experiment). Phage f1, administered 2 weeks after infection, was entirely effective in sterilizing the animals, as shown by microscopic analysis (Figure 2 ) and confirmed by bacteriological tests (data not shown).
Host density threshold. Mice were infected with a sublethal dose of Salp572 f1S bacteria (10 6 CFUs per mouse) and 2 d later treated with phage f1 (10 7 PFUs per mouse). Circulating bacteria and phages were measured at 2-d intervals for 14 d. Phage replication began only when the concentration of the Salp572 f1S bacteria in the blood was у10 4 CFU/mL ( Figure 3A) . The same threshold was also required for phage replication in the GI tract and liver ( Figures 3B and 3C) . Thus, phages, in common with other microbial predators [25] , display a density threshold for reproduction. This notion, as discussed below, is important for a correct clinical use of phage therapy.
Phage f1 resistance produces loss of virulence. In vivo and in vitro experiments have demonstrated that acquiring resistance to a phage or to an antibiotic imposes a fitness cost [26] [27] [28] [29] . This study exploited acquisition of resistance to phage f1 as a means to curb the virulence of the wild Salp572 f1S strain and to use the avirulent phage-resistant derivative strain (Salp572 f1R ) to protect mice from infection. The phage-resistant strain Salp572 f1R was isolated from the phage-susceptible strain Salp572 f1S in the presence of phage f1. The common origin of the parental and derivative strains is documented by their similar genomic profiles ( Figure 1D ). Salp572 f1R was fully resistant to phage f1 ( Figure 4A ). Prolonged liquid subculture for several months in the absence of the phage, storage at Ϫ80ЊC, and passages in vivo did not alter the resistance of Salp572 f1R to phage f1. On LB agar, Salp572 f1R , compared with the parental strain, formed smaller colonies (data not shown); Salp572 f1R also displayed reduced size and a translucent and thickened cell wall ( Figures 4B and 4C) , loss of the O-antigen, reduced growth rate during the exponential growth phase (after incubation for 3 h, broth cultures of the wild-type Salp572 f1S strain and of the mutant Salp572 f1R strain had an OD 600 nm of 0.6 and 0.2, respectively), and increased doubling time (mean doubling time of Salp572 f1S ‫ע‬ SD, min; mean dou-30 ‫ע‬ 3.5 bling time of Salp572 f1R ‫ע‬ SD, min). Acquisition of 45 ‫ע‬ 2.8 phage resistance also altered the transcriptional profile of Salp572 f1R . The 6 virulence genes that were analyzed were all . This result suggests that protective immunity is probably elicited by a gene (or multiple genes) that are induced during infection. The experiment was repeated once more with a vaccine of live Salp572 f1R and S. enterica serovar Dublin, S. enterica serovar Typhimurium, or S. enterica serovar Virchow as challenging bacteria (10 7 CFUs per mouse). The mice of the control groups (5 mice per group) all died within 2-3 d; at the end of the experiment (5 weeks after infection), all the mice immunized with Salp572 f1R (10 mice per group) were alive. These data show that the Salp572 f1R Figure 4 . Resistance of the Salp572 f1R strain to bacteriophage f1. A, Evidence that the presence of phage f1 did not interfere with in vitro multiplication of the Salp572 f1R strain. Electron micrographs of the f1-resistant (Salp572 f1S ) (B) and f1-susceptible (Salp572 f1R ) (C) strains in the presence of phage f1. Phage f1 lysed only the Salp572 f1S strain. In addition, Salp572 f1R bacteria displayed reduced cell size and thickened cell walls. OD 600 nm , optical density at 600 nm. vaccine is effective only when alive and, in this state, is active against different S. enterica serovars. Live attenuated Salmonella strains can provide short-term, nonspecific protection because of persisting vaccine bacteria [33] . The Salp572 f1R strain is cleared within 7 d after administration. Therefore, the protection described in this study cannot be a result of a nonspecific immune response.
Anti-Salp572 f1R antibodies protect against Salp572 f1R infection. One group of 10 mice was injected intravenously with 10 mL of normal rat serum (control mice). A second group of 10 mice was injected with 10 mL of serum from rats immunized with Salp572 f1R . The next day, both groups of animals were challenged with a lethal dose of Salp572 f1S (10 7 CFUs per mouse). Survival was monitored for 14 d. The anti-Salp572 f1R rat serum provided protection to 10 of 10 mice, whereas all 10 of 10 control mice died within 2 d. At the end of the experiment, the blood, livers, and GI tracts of mice passively immunized with anti-Salp572 f1R antibodies were sterile, whereas at time of death, the blood, livers, and GI tracts of the control mice displayed a high bacterial load (mean bacterial load ‫ע‬ SD, CFU/mL in the blood and 6 6 6 4 ϫ 10 ‫ע‬ 0.4 ϫ 10 6.5 ϫ 10 ‫ע‬ CFU/g in the GI tract). 
DISCUSSION
The purpose of this study was to review the therapeutic potential of phages. First, we showed that phages are highly effective when administered 2 weeks after the experimental in-fection; second, we showed that bacteria that gain phage resistance are often avirulent (or scarcely virulent) and do not survive in vivo for long. These results alone invite an objective assessment of phage prospects as antimicrobials. The study also shows that phage-resistant bacteria, with their reduced virulence, can be excellent vaccines. Selection for phage resistance as a straightforward approach to the production of vaccines is a new and significant contribution of phages to the control of bacterial diseases. It is also the most important result of this study.
Phage f1, given concurrently with a lethal dose of Salp572 f1S , rescued 100% of the animals. More importantly, the same phage, administered 2 weeks after the experimental infection with a sublethal dose of Salp572 f1S , sterilized 100% of the animals ( Figure 2 ). The infection model that used a small initial bacterial inoculum shows clearly the true potential of phages and brings phage therapy closer to the preclinical testing phase. Sterilization was attained in all of the target organs (liver and GI tract) and in the blood without bacterial rebound. The same results were also observed in another study, which involved a different phage (M Sa ) and a different pathogen (Staphylococcus aureus) [34] . The conclusion that phages do not have a temporal limit on their ability to kill bacteria therefore seems of general significance. In none of the experiments did phage f1 cause adverse effects that could be attributed to the rapid lysis of bacteria, nor did the phage therapy induce neutralizing antibodies, despite claims that it might [12, 13] . The same results were also observed in another study with phage M Sa [34] . Mice inoculated with Salp572 f1R bacteria returned to being sterile within 7 d. To exclude the possibility that this finding was peculiar to Salp572 f1R bacteria, 2 more phage f1-resistant mutants isolated from S. enterica Paratyphi B and 2 phage f1-resistant mutants isolated from S. enterica Dublin were inoculated intravenously into mice. Again, within 4-7 d, the mice were sterile. Reduced survival in vivo has also been reported for phage-resistant strains of Vibrio cholerae [29, 35] , enteropathogenic Escherichia coli [36] , and Campylobacter jejuni [28] . Although the above data do not downplay the possibility that resistant bacteria might occasionally emerge in the course of phage therapy, they do collectively indicate that resistant strains in vivo are generally cleared by innate immunity (at least more often than has been suspected so far). It has recently been reported that phage-resistant bacteria in vitro display little or no fitness cost, in comparison with the original susceptible bacteria [14] . The same phenomenon has also been observed in the course of the present study. However, the point that needs to be stressed is that what is observed in vitro does not necessarily reflect what happens in vivo (in the presence of the immune system). The finding of an inverse association between the presence of virulent phages and susceptible bacteria (Figure 3) is of significance for a sounder use of phage therapy. It explains why, contrary to what occurs with antibiotics, early phage administration (when bacterial density is below the threshold) might be counterproductive. This finding also helps in deciding when to use a single phage dose and when multiple doses are necessary. If the target bacterial population is replicating rapidly, then 1 phage dose is sufficient ( Figure 3) ; if bacteria replicate slowly-as in the abscesses-then multiple doses are definitely more effective than 1 dose [34] . The dynamics of the interactions between phages and bacteria might also help us to understand the forces regulating the cyclical nature of salmonellosis and serovar changes [1, 2, 37] . We can hypothesize that, as in the case of cholera [38, 39] , if lysogenic and nonlysogenic bacterial strains of S. enterica were present in the same environment, then the lysogenic strains would liberate phages that attack nonlysogenic strains, which would cause cyclical bacterial strain replacement.
The Centers for Disease Control and Prevention estimate the annual number of cases of salmonellosis in the United States at ∼1.4 million [37] . The emergence of antibiotic-resistant strains of S. enterica [1] makes treatment of these patients more difficult and, at the same time, the need for a vaccine more urgent. In view of the complex array of virulence factors produced by the many S. enterica serovars, it is unlikely that a vaccine targeting a single virulence factor (ie, a subunit vaccine) might be satisfactory. In addition, the factor targeted by a subunit vaccine might have limited distribution among clinical isolates or might not be expressed in vivo. However, if the factor is common among S. enterica serovars, then preexisting antibodies in the host might neutralize the vaccine before it can be effective, as was shown in a different context [40] . A multiple-component vaccine, in the form of an attenuated strain of S. enterica, therefore seemed to be the appropriate choice, and selection for phage resistance-which often occurs at the expense of virulence [28, 29, 41 ]-seemed to be the simplest approach to a multiple-component vaccine. The phage-susceptible virulent strain Salp572 f1S was grown in vitro in the presence of phage f1. As expected, compared with the parental strain, the phage-resistant strain Salp572 f1R was much attenuated in vivo as a result of down-regulation of numerous virulence genes ( Figure 5A ). The Salp572 f1R strain was fully protective against different S. enterica serovars, provided protection in antibody transfer experiments, and protected mice from inflammation ( Figure 5B ). One potential concern about using the Salp572 f1R strain as vaccine is its reversion to phage sensitivity and the accompanying virulent phenotype. However, the Salp572 f1R strain showed (in vitro and in vivo) remarkable stability, which presumably reflects the drastic and irreversible changes ( Figure 5A ) that accompanied acquisition of phage resistance. The data reported here have some limitations that need to be discussed. First, the fitness cost imposed on bacteria to gain phage resistance does not refer to virulence alone but also refers to environmental fitness (the ability to compete with wild-type strains in nature). This means that one cannot assume with certainty that all phage-resistant strains are attenuated enough to be used as a vaccine. Second, knowing the genome size of phage f1 (30-35 kb) ( Figure 1B) is not sufficient to conclude that phage f1 is different from the Salmonella phages deposited in public databases. However, given the vast phage genetic diversity-such that "no genomically defined phage has been isolated more than once" [42, p 171]-the hypothesis that phage f1 is unique seems reasonable. Third, the O-antigen is the attachment site for many gram-negative phages, especially Salmonella phages [43, 44] . Salp572 f1R bacteria, in common with several Salmonella strains, acquired phage resistance by losing the O-antigen [30] [31] [32] . However, at present, we cannot exclude the possibility that, in addition to O-antigen loss, other mechanisms also contribute to protect Salp572 f1R bacteria against phage f1. In conclusion, despite leaving some issues undefined (the phage f1 sequence and a detailed analysis of the Salp572 f1R strain conversion from phage susceptible to phage resistant), the data presented in this study have important implications for the role that phages can have as antimicrobials.
